On March 13, 2026, China’s National Medical Products Administration quietly did something no regulator on earth had done before: approved an invasive brain-computer interface for commercial sale. Not a clinical trial. Not a research exemption. A product. By June, Neuracle Medical Technology’s NEO implant was surgically placed in a patient who’d lost hand function to a spinal cord injury roughly a decade earlier. Neuralink, meanwhile, remains in FDA trial limbo — the tech world’s most famous “coming soon” since roughly 2019.
A Coin-Sized Chip, a Robotic Glove, and the End of “Someday”
NEO doesn’t read your thoughts — it reads one very specific intention and turns it into grip strength.
Losing the ability to hold a fork, then regaining it by thinking about closing your hand — that’s NEO’s narrow, remarkable purpose. The coin-sized implant embeds in the skull. Eight electrodes rest on the dura mater — the brain’s outer protective membrane — above the sensorimotor cortex, never piercing brain tissue. Surgery takes about 90 minutes, according to MIT Technology Review.
When a patient imagines hand movement, NEO captures those neural signals wirelessly. An external computer decodes them in real time, driving a soft pneumatic robotic glove on the paralyzed hand.
The scope stays deliberately tight: adults 18–60 with quadriplegia from cervical spinal cord injury. Not speech. Not vision. Not general movement. Across 36 clinical procedures — four feasibility trials plus 32 multi-center studies — all participants showed grasping improvement, with some exhibiting signs of neural remodeling, according to Nature. NEO’s epidural, non-penetrating design trades some signal fidelity for safety and regulatory tractability. It’s a precision tool solving one specific, devastating problem — and that precision is exactly why it cleared approval.
Neuralink Is Watching. So Is Washington.
The geopolitical dimension of a medical device approval tells you everything about where neurotech is headed.
Neuralink’s N1 implant threads ultra-thin electrodes directly into cortical tissue, capturing richer signal data. Think of NEO as listening through a wall while Neuralink puts its ear against the speaker. But NEO crossed the regulatory finish line first. China designated BCIs as a core strategic technology in its latest five-year plan, alongside quantum computing and AI robotics, according to Gizmodo. Neuracle, backed by Tsinghua University research, has forced a conversation regulators in Washington and Brussels can no longer defer.
The ethical questions haven’t been answered: who owns the neural data these devices collect?
Unconfirmed reports suggest NEO may be added to China’s national health insurance system — but that claim awaits primary regulatory confirmation. If it holds, that’s not a gadget story. That’s infrastructure for scaling brain-computer rehabilitation nationally.
Your next question shouldn’t be whether brain chips work. It should be who gets to define the rules around them — and whether the FDA’s timeline gives anyone else a say.
